Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with atrial fibrillation (AF) anytime in the baseline period or on the index date, also have definitive diagnosis of AF anytime in the baseline period, on the index date, or post-index period.~* Prescribed apixaban or warfarin on or after the day of AF diagnosis. The first observed prescription will be used to identify the patient's index date and treatment cohort~* No use of the any oral anticoagulants (OACs) during the baseline period (the 180 days before the index date)~* Age of 18 years or older on the index date~Exclusion Criteria:~* Having a diagnosis of valvular atrial fibrillation, post-operative atrial fibrillation, rheumatic atrial fibrillation or mechanical-valvular atrial fibrillation during the baseline and post-index period~* Having a procedure of prosthetic heart valve during the baseline period~* Having a cardiac surgery procedure record during the baseline period~* Having a diagnosis of venous thromboembolism during the baseline period~* Having a hemodialysis during the baseline period~* Female patients with pregnancy during the baseline and follow-up period~* Patients prescribed apixaban other than approved daily dose (\<5 mg or \>10 mg)~* Patients prescribed OACs during baseline period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).